Last reviewed 2026-05-25 · How we verify

(+/-)-Inaperisone (INAPERISONE)

Phase 2 active Small molecule ✓ Verified May 2026

(+/-)-Inaperisone (generic name: INAPERISONE) is a drug. It is currently in Phase 2 development.

INAPERISONE is thought to work by interacting with a specific target in the body to produce a therapeutic effect.

(+/-)-Inaperisone is a small molecule. It is also known by the synonyms INAPERISONA and INAPERISONE.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	INAPERISONE
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine INAPERISONE as a key that fits into a lock in the body. When it binds to this lock, it triggers a series of events that help to treat a particular condition. This process is complex and involves many different molecules and pathways, but essentially, INAPERISONE helps to restore balance and normal function to the body.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

(+/-)-Inaperisone CI brief — competitive landscape report
(+/-)-Inaperisone updates RSS · CI watch RSS

Frequently asked questions about (+/-)-Inaperisone

What is (+/-)-Inaperisone?

(+/-)-Inaperisone (INAPERISONE) is a Small molecule drug.

How does (+/-)-Inaperisone work?

INAPERISONE is thought to work by interacting with a specific target in the body to produce a therapeutic effect.

What is the generic name of (+/-)-Inaperisone?

INAPERISONE is the generic (nonproprietary) name of (+/-)-Inaperisone.

What development phase is (+/-)-Inaperisone in?

(+/-)-Inaperisone is in Phase 2.

Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing